EssilorLuxottica has received De Novo marketing authorization from the U.S. FDA for the Essilor Stellest ophthalmic lens — the first and only spectacle lens authorized in the United States to slow the progression of myopia in children, with an average efficacy of 71% over two years compared to single-vision lenses.
The FDA granted De Novo marketing authorization to the Essilor Stellest lens, making it the first and only spectacle lens officially authorized in the United States to slow the progression of myopia in children.
Clinical studies demonstrated that Essilor Stellest slowed myopia progression by an average of 71% over two years compared with single-vision lenses, based on a prospective, randomized, double-masked clinical trial conducted in the United States.
The clinical trial included children aged 6 to 12 at the start of treatment. EssilorLuxottica indicates that the lens will be available to U.S. eyecare professionals “in the coming weeks,” following its rollout in other markets worldwide.
This authorization marks a shift from traditional corrective eyewear to medically recognized vision solutions. Following its “Breakthrough Device” designation in 2021, Stellest is entering a new phase in the clinical management of myopia.
Myopia is rising rapidly worldwide and is expected to affect nearly half of the global population by 2050, including hundreds of millions of children. In North America, it already affects over 40% of adults and roughly one in four children.
Because the FDA’s De Novo authorization positions Essilor Stellest as the first spectacle lens officially approved in the United States to slow myopia progression in children — transforming a technological innovation into a recognized health solution.
Further reading :
Online as in a shop window, the image comes before the words: it is what the customer studies, what reassures them or cheapens a frame chosen with care. Yet eyewear is one of the hardest objects to photograph — lens and material bounce light in different ways. This is the practical guide to eyewear photography […]
On June 23, 2026, Meta and EssilorLuxottica unveiled Meta Glasses, a new line of smart eyewear. After Ray-Ban Meta and Oakley Meta, it is the first time the wearable carries Meta’s own name — a sign that connected eyewear is establishing itself as a standalone optical category rather than a piece of technology grafted onto […]
Linda Farrow doesn’t do nostalgia. With the Iconic Collection, the British house revisits its founding vocabulary — the forms that defined it in 1970 — and reengineers them for a generation that never saw the originals. This is not a reissue. It is a restatement. A Return to Origins That Refuses to Romanticise Founded in […]
There is something almost paradoxical about EssilorLuxottica’s stock market trajectory in 2026. The group continues to post sales figures most companies would envy — +11.7% at constant exchange rates in Q3 2025, +11.2% for the full year, and +10.8% again in Q1 2026. Yet over six months, its share price has erased more than 40% […]
What Paloceras built with the Pebble series, then translated into prescription eyewear with Nouvelle Fiction optical, now reaches its third chapter: a sunglasses collection that preserves the house’s sculptural grammar while turning it toward the light. Nouvelle Fiction Sun is not a spin-off. It is a continuation — on its own terms. From Optical to […]
Thirty years after their debut, Oakley Jackets are no longer just evolving. They are redefining what sports eyewear can be — and what it represents. In 1994, Oakley introduced a frame that didn’t exist before. Wraparound, bold, engineered not to please but to perform. In 2026, that same mindset expands into a broader vision: a […]